S&P 500 Futures
(0.13%) 5 138.25 points
Dow Jones Futures
(0.08%) 38 472 points
Nasdaq Futures
(0.22%) 17 885 points
Oil
(-0.26%) $83.63
Gas
(1.72%) $1.956
Gold
(0.11%) $2 349.80
Silver
(0.41%) $27.65
Platinum
(1.46%) $935.60
USD/EUR
(-0.07%) $0.934
USD/NOK
(-0.19%) $11.00
USD/GBP
(-0.19%) $0.799
USD/RUB
(1.28%) $93.05

Sanntidsoppdatering for Prescient Therapeutics [PTX.AX]

Børs: ASX Industri: Pharmaceuticals, Biotechnology & Life Sciences
Sist oppdatert29 apr 2024 @ 08:10

0.00% $ 0.0520

Live Chart Being Loaded With Signals

Commentary (29 apr 2024 @ 08:10):
Profile picture for Prescient Therapeutics Ltd

Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-200, which is in Phase 2a clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent or persistent platinum-resistant ovarian cancer; and PTX-100, a RhoA inhibitor, for hematological and solid malignancies that focuses on cancers with Ras and RhoA mutations...

Stats
Dagens volum 762 848
Gjennomsnittsvolum 1.17M
Markedsverdi 41.88M
EPS $0 ( 2024-02-21 )
Last Dividend $7.15 ( 1993-10-21 )
Next Dividend $0 ( N/A )
P/E -5.20
ATR14 $0.00100 (1.89%)

Prescient Therapeutics Korrelasjon

10 Mest positive korrelasjoner
10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Prescient Therapeutics Økonomi

Annual 2023
Omsetning: $2.43M
Bruttogevinst: $2.43M (99.91 %)
EPS: $-0.00960
FY 2023
Omsetning: $2.43M
Bruttogevinst: $2.43M (99.91 %)
EPS: $-0.00960
FY 2022
Omsetning: $1.89M
Bruttogevinst: $1.89M (99.93 %)
EPS: $-0.00790
FY 2021
Omsetning: $0.00
Bruttogevinst: $0.00 (0.00 %)
EPS: $-0.00680

Financial Reports:

No articles found.

Prescient Therapeutics Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)

Prescient Therapeutics Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future
Information
First Dividend $5.72 1990-10-25
Last Dividend $7.15 1993-10-21
Next Dividend $0 N/A
Payout Date 1993-12-31
Next Payout Date N/A
# dividends 2 --
Total Paid Out $12.87 --
Avg. Dividend % Per Year 0.00% --
Score 0.22 --
Div. Sustainability Score 0
Div.Growth Potential Score 0
Div. Directional Score 0 --
Next Divdend (Est)
(2026-10-05)
$0 Estimate 0.00 %
Dividend Stability
0.00 Very Bad
Dividend Score
0.22
Pay Frequency
Sporadic
Yearly Payout
Year Amount Yield

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for ASX

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
YAL.AX Ex Dividend Knight 2023-09-05 Annually 0 0.00%
FGG.AX Ex Dividend Junior 2023-10-05 Annually 0 0.00%
PMV.AX Ex Dividend Knight 2023-06-20 Semi-Annually 0 0.00%
ARG.AX Ex Dividend Knight 2023-08-25 Semi-Annually 0 0.00%
IFL.AX Ex Dividend Junior 2023-09-07 Semi-Annually 0 0.00%
SDG.AX Ex Dividend Knight 2023-10-24 Quarterly 0 0.00%
CCP.AX Ex Dividend Knight 2023-09-18 Annually 0 0.00%
MCY.AX Ex Dividend Knight 2023-09-13 Semi-Annually 0 0.00%
TGF.AX Ex Dividend Junior 2023-09-07 Semi-Annually 0 0.00%
CUV.AX Ex Dividend Knight 2023-09-05 Annually 0 0.00%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM-2.491.500-10.00-10.00[0 - 0.5]
returnOnAssetsTTM-0.3131.200-10.00-10.00[0 - 0.3]
returnOnEquityTTM-0.3181.500-4.65-6.97[0.1 - 1]
payoutRatioTTM0-1.00000[0 - 1]
currentRatioTTM10.260.80010.008.00[1 - 3]
quickRatioTTM9.960.80010.008.00[0.8 - 2.5]
cashRatioTTM3.081.50010.0010.00[0.2 - 2]
debtRatioTTM0-1.50000[0 - 0.6]
interestCoverageTTM01.000-1.111-1.111[3 - 30]
operatingCashFlowPerShareTTM-0.009522.00-0.00317-0.00635[0 - 30]
freeCashFlowPerShareTTM-0.009522.00-0.00476-0.00952[0 - 20]
debtEquityRatioTTM0-1.50000[0 - 2.5]
grossProfitMarginTTM1.0001.00010.0010.00[0.2 - 0.8]
operatingProfitMarginTTM-3.711.000-10.00-10.00[0.1 - 0.6]
cashFlowToDebtRatioTTM01.000-1.111-1.111[0.2 - 2]
assetTurnoverTTM0.1260.800-2.50-1.996[0.5 - 2]
Total Score-0.920

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM-5.511.000-0.6580[1 - 100]
returnOnEquityTTM-0.3182.50-2.99-6.97[0.1 - 1.5]
freeCashFlowPerShareTTM-0.009522.00-0.00317-0.00952[0 - 30]
dividendYielPercentageTTM01.50000[0 - 0.4]
operatingCashFlowPerShareTTM-0.009522.00-0.00317-0.00635[0 - 30]
payoutRatioTTM01.50000[0 - 1]
pegRatioTTM-1.9111.500-10.000[0.5 - 2]
operatingCashFlowSalesRatioTTM-2.461.000-10.000[0.1 - 0.5]
Total Score-2.81

Prescient Therapeutics

Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-200, which is in Phase 2a clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent or persistent platinum-resistant ovarian cancer; and PTX-100, a RhoA inhibitor, for hematological and solid malignancies that focuses on cancers with Ras and RhoA mutations. It has a strategic collaboration with The University of Texas MD Anderson Cancer Center to develop blood cancer binder for OmniCAR. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited was incorporated in 1986 and is based in Melbourne, Australia.

Om Live Signaler

Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.

Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.